# Phase 3 melanoma trials recruiting: 22 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 22 trials in phase 3 for melanoma that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 3 melanoma trials: 22 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-3/melanoma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 22
- Recruiting or not yet: 22
- Read on: November 19, 2026

## Trials

The 22 newest of 22, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 22, 2026 | NCT07890415 | Using an Artificial Intelligence (AI) Tool for Melanoma Diagnosis | Memorial Sloan Kettering Cancer Center | Phase 3 | Recruiting | Malignant Melanoma of Skin, Other and Unspecified Malignant Neoplasm of Skin, Melanoma in Situ, Carcinoma in Situ of... | 14,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07890415) |
| September 11, 2026 | NCT07815574 | iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma | Scancell Ltd | Phase 3 | Not yet recruiting | Melanoma (Skin Cancer), Advanced Melanoma, Metastatic Melanoma, Skin Cancer | 550 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07815574) |
| September 4, 2026 | NCT07804186 | Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma | IDEAYA Biosciences | Phase 3 | Recruiting | Uveal Melanoma | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07804186) |
| April 27, 2026 | NCT07552597 | Superparamagnetic Iron Oxide for Sentinel Lymph Node Localization in Patients With Cutaneous Melanoma: MagMen-II | Vastra Gotaland Region | Phase 3 | Not yet recruiting | Melanoma (Skin Cancer) | 254 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07552597) |
| April 15, 2026 | NCT07530887 | NO Re-excision MelanomA - NORMA 2 | Sponsor not shown (see the record) | Phase 3 | Recruiting | Melanoma (Skin Cancer) | 1,749 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07530887) |
| October 28, 2025 | NCT07221734 | Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated... | mAbxience Research S.L. | Phase 3 | Recruiting | Advanced (Unresectable or Metastatic) Melanoma | 632 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07221734) |
| July 16, 2025 | NCT07068074 | Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With... | ECOG-ACRIN Cancer Research Group | Phase 3 | Recruiting | Cutaneous Melanoma | 428 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07068074) |
| June 11, 2025 | NCT07015190 | Neoadjuvant Darovasertib in Primary Uveal Melanoma | IDEAYA Biosciences | Phase 3 | Recruiting | Uveal Melanoma | 520 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07015190) |
| January 27, 2025 | NCT06794775 | SWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III Melanoma | Sponsor not shown (see the record) | Phase 3 | Recruiting | Malignant Melanoma Stage III | 128 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06794775) |
| December 19, 2024 | NCT06743126 | SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma | Immatics US, Inc. | Phase 3 | Recruiting | Melanoma, Cutaneous Malignant, Mucosal Melanoma | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06743126) |
| July 25, 2024 | NCT06519266 | PHP in Combination With IPI1/NIVO3 Compared to IPI3/NIVO1 Only in Patients With Uveal Melanoma Liver Metastases | Vastra Gotaland Region | Phase 3 | Recruiting | Uveal Melanoma, Liver Metastases | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06519266) |
| February 7, 2024 | NCT06246916 | A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony... | Regeneron Pharmaceuticals | Phase 3 | Recruiting | Melanoma | 560 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06246916) |
| February 7, 2024 | NCT06246149 | Adjuvant Tebentafusp in High Risk Ocular Melanoma | European Organisation for Research and Treatment of Cancer - EORTC | Phase 3 | Recruiting | Uveal Melanoma | 290 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06246149) |
| August 23, 2023 | NCT06008106 | Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma | Shanghai Kechow Pharma, Inc. | Phase 3 | Recruiting | Melanoma | 165 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06008106) |
| June 12, 2023 | NCT05899465 | Perioperative Treatment With Tranexamic Acid in Melanoma | University of Aarhus | Phase 3 | Recruiting | Melanoma | 1,204 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05899465) |
| May 22, 2023 | NCT05868707 | OH2 Injection in Melanoma | Binhui Biopharmaceutical Co., Ltd. | Phase 3 | Recruiting | Melanoma | 340 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05868707) |
| February 14, 2023 | NCT05727904 | Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced... | Iovance Biotherapeutics, Inc. | Phase 3 | Recruiting | Metastatic Melanoma, Unresectable Melanoma, Melanoma | 670 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05727904) |
| September 22, 2022 | NCT05549297 | Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM) | Immunocore Ltd | Phase 3 | Recruiting | Advanced Melanoma | 540 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05549297) |
| August 31, 2022 | NCT05522660 | Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small... | ETOP IBCSG Partners Foundation | Phase 3 | Recruiting | Non-Small Cell Lung Cancer, Melanoma | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05522660) |
| August 16, 2022 | NCT05502900 | Adjuvant Melatonin for Uveal Melanoma | Sponsor not shown (see the record) | Phase 3 | Recruiting | Uveal Melanoma, Uveal Melanoma, Posterior, Medium/Large Size, Eye Cancer, Intraocular Melanoma | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05502900) |
| June 26, 2018 | NCT03567889 | Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients | Philogen S.p.A. | Phase 3 | Recruiting | Melanoma Stage IIIB, Melanoma Stage IIIC, Melanoma Stage IIID | 186 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03567889) |
| July 1, 2016 | NCT02821013 | Duration of Anti-PD-1 Therapy in Metastatic Melanoma | Canadian Cancer Trials Group | Phase 3 | Recruiting | Unresectable/Metastatic Melanoma | 614 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02821013) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| IDEAYA Biosciences | 2 |
| Vastra Gotaland Region | 2 |
| Canadian Cancer Trials Group | 1 |
| European Organisation for Research and Treatment of Cancer - EORTC | 1 |
| Immunocore Ltd | 1 |
| Binhui Biopharmaceutical Co., Ltd. | 1 |
| [Philogen S.p.A.](https://specstream.ai/data/clinical-trials/company/philogen-s-p-a) | 1 |
| [Regeneron Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/regeneron-pharmaceuticals) | 1 |
| Iovance Biotherapeutics, Inc. | 1 |
| University of Aarhus | 1 |
| Memorial Sloan Kettering Cancer Center | 1 |
| mAbxience Research S.L. | 1 |
| Shanghai Kechow Pharma, Inc. | 1 |
| Scancell Ltd | 1 |
| Immatics US, Inc. | 1 |
| ECOG-ACRIN Cancer Research Group | 1 |
| ETOP IBCSG Partners Foundation | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 11 |
| United Kingdom | 8 |
| Canada | 7 |
| Spain | 7 |
| Netherlands | 6 |
| Switzerland | 6 |
| Sweden | 5 |
| Australia | 5 |
| France | 5 |
| Germany | 5 |
| Italy | 5 |
| Belgium | 4 |
| Poland | 3 |
| Israel | 3 |
| Austria | 2 |
| China | 2 |
| Denmark | 2 |
| Greece | 2 |
| Slovakia | 2 |
| Czechia | 1 |
| Estonia | 1 |
| New Zealand | 1 |
| Slovenia | 1 |
| Finland | 1 |
| Singapore | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Indo Chinese restaurants in the United States](https://specstream.ai/data/businesses/indo-chinese-restaurants/united-states)
- [Burmese restaurants in the United States](https://specstream.ai/data/businesses/burmese-restaurants/united-states)
- [Shared office spaces in the United States](https://specstream.ai/data/businesses/shared-office-spaces/united-states)
- [Hyperbaric medicine centers in the United States](https://specstream.ai/data/businesses/hyperbaric-medicine-centers/united-states)
- [British restaurants in the United States](https://specstream.ai/data/businesses/british-restaurants/united-states)
- [Screen printers in the United States](https://specstream.ai/data/businesses/screen-printers/united-states)
